Journal
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY
Volume 11, Issue -, Pages 11-24Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/BLCTT.S245191
Keywords
multiple myeloma; BCL2 family inhibitors; venetoclax
Categories
Ask authors/readers for more resources
Despite progress in multiple myeloma treatment, many patients still require multiple lines of therapy. BCL2 family inhibitors offer a promising new class of drugs with potential activity as single agents or in combination. Venetoclax, a BCL2 specific inhibitor, shows encouraging results when used in combination with other myeloma therapies.
Although much progress has been made in the treatment of multiple myeloma, the majority of patients fail to be cured and require numerous lines of therapy. Inhibitors of the BCL2 family represent an exciting new class of drugs with a novel mechanism of action that are likely to have activity as single agents and in combination with existing myeloma therapies. The BCL2 proteins are oncogenes that promote cell survival and are frequently upregulated in multiple myeloma, making them attractive targets. Venetoclax, a BCL2 specific inhibitor, is furthest along in development and has shown promising results in a subset of myeloma characterized by the t(11;14) translocation. Combining venetoclax with proteasome inhibitors and monoclonal antibodies has improved responses in a broader group of patients, but has come at the expense of a toxicity safety signal that requires additional follow-up. MCL1 inhibitors are likely to be effective in a broader range of patients and are currently in early clinical trials. This review will cover much of what is known about the biology of these drugs, biomarkers that predict response, mechanisms of resistance, and unanswered questions as they pertain to multiple myeloma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available